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OBJECTIVES This study evaluated the prognosis of patients resuscitated from ventricular tachycardia (VT)
or ventricular fibrillation (VF) with a transient or correctable cause suspected as the cause of
the VT/VF.
BACKGROUND Patients resuscitated from VT/VF in whom a transient or correctable cause has been
identified are thought to be at low risk for recurrence and often receive no primary treatment
for their arrhythmias.
METHODS In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, patients with a
potentially transient or correctable cause of VT/VF were not eligible for randomization. The
mortality of these patients was compared with the mortality of patients with a known high
risk of recurrence of VT/VF in the AVID registry.
RESULTS Compared with patients having high risk VT/VF, those with a transient or correctable cause
for their presenting VT/VF were younger and had a higher left ventricular ejection fraction.
These patients were more often treated with revascularization as the primary therapy, more
commonly received a beta-blocker, less often required therapy for congestive heart failure and
less commonly received either an antiarrhythmic drug or an implantable cardioverter
defibrillator. Nevertheless, subsequent mortality of patients with a transient or correctable
cause of VT/VF was no different or perhaps even worse than that of the primary VT/VF
population.
CONCLUSIONS Patients identified with a transient or correctable cause for their VT/VF remain at high risk
for death. Further research is needed to define truly reversible causes of VT/VF. Meanwhile,
these patients may require more aggressive evaluation, treatment and follow-up than is
currently practiced. (J Am Coll Cardiol 2001;38:1718–24) © 2001 by the American College
of Cardiology
The Antiarrhythmics Versus Implantable Defibrillators
(AVID) trial was a prospective, randomized comparison of
antiarrhythmic drugs versus implantable cardioverter defi-
brillators in patients with life-threatening sustained ventric-
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ular arrhythmias (1–3). Patients qualified for randomization in
the AVID trial if they had serious ventricular arrhythmias not
due to a transient or correctable cause. These arrhythmias
included: 1) ventricular fibrillation (VF); 2) sustained ventric-
ular tachycardia (VT) with syncope; or 3) sustained VT causing
angina, near-syncope, hypotension or congestive heart failure
(CHF) with a left ventricular ejection fraction 0.40.
Patients with sustained VT or VF who do not have an
identifiable transient or potentially correctable cause are at
high risk for recurrence of serious ventricular arrhythmias
and subsequent death (4–6). Conversely, it is believed that
sustained VT or VF due to an identifiable transient or
correctable cause has a low subsequent risk of death, as long
as the transient cause is corrected. This bit of conventional
wisdom has not been critically evaluated. A registry (3) was
maintained of all patients screened for the AVID trial. The
AVID registry included a category of patients whose pre-
senting ventricular arrhythmias were considered to be due to
a transient or potentially correctable cause.
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The purpose of this analysis was to examine mortality for
patients in the AVID registry with sustained VT or VF due
to a putative transient or correctable cause in comparison
with mortality for patients with VT/VF known to be at high
risk. Our hypothesis was that patients with a transient or
correctable cause identified for their VT/VF would have a
lower risk of death.
METHODS
Both the AVID trial (1) and the AVID registry (3) have
been described previously. Briefly, patients at 56 clinical
sites were screened for inclusion in the randomized portion
of the AVID trial. All patients had sustained ventricular
arrhythmias, although some patients were not eligible for
randomization. Patients who were screened for randomiza-
tion in AVID and who gave informed consent were entered
into a registry if they met certain predetermined criteria, and
mortality of all such patients was determined whether or not
they were randomized. The date of death of patients was
determined by routine follow-up in the main randomized
portion of the AVID trial or by the National Death Index
Service (NDIS) (a nationwide system that records all
deaths) in the nonrandomized portion of AVID. Entries
into the NDIS are usually accomplished no later than one
year after the actual death date, and data are updated near
the end of every calendar year. The NDIS database used
here was obtained at the end of 1998, which would include
all deaths that had occurred through the end of calendar
year 1997.
The categories of ventricular arrhythmias compared in
this study are outlined in Table 1. The 145 patients with
documented sustained VT with an ejection fraction 0.40
(fourth group in Table 1) were not eligible for randomiza-
tion in AVID but are included in this comparison because
there was no ejection fraction limitation imposed on the
patients with presumed transient causes for their arrhyth-
mias. Furthermore, a previous AVID registry study showed
that these patients, indeed, have a high risk for death (6).
Patients whose VT/VF was associated with a transient or
correctable cause were further classified by the nature of the
reversible factor: new Q-wave myocardial infarction (MI),
new non–Q-wave MI, other ischemic event, proarrhythmic
drug reaction, electrolyte imbalance (hypokalemia or hypo-
magnesemia) or other causes. The determination that
VT/VF had a transient or correctable cause was made by the
AVID principal investigator at each site based on directions
provided in the manual of operations. These patients were
treated under the direction of their own physicians, and the
initial treatment strategy was recorded in the registry. The
AVID studies and their consent forms received approval
from the institutional review board at each site.
Continuous variables are presented as mean  one SD.
Categorical variables are presented as percentages. Compar-
ative analyses included two-tailed t test for continuous
variables and chi-square test for discrete variables. Given
multiple comparisons, we considered p 0.01 significant in
these comparisons. Survival estimates for the populations
were based on the methods of Kaplan and Meier. Compar-
isons among groups were made by the global log-rank test.
Survival was adjusted using a Cox proportional hazard
model, stratifying on potential confounders (variables that
distinguished groups and predicted mortality) and including
other factors that predicted mortality as covariates. In the
last two analyses, p 0.05 was considered statistically
significant.
RESULTS
A total of 5,989 patients were screened, and 4,450 patients
were entered in the registry. For appropriate comparisons,
only the patients whose arrhythmias occurred out-of-
hospital and for whom an NDIS search was possible were
included in this study (first four arrhythmia groups in Table
1, n 2,013). A group of 278 patients was identified whose
VT/VF was thought to be due to a transient or correctable
cause. These last patients form the main focus of this report.
Table 2 classifies the presumed transient or correctable
causes for the presenting VT/VF. Most patients had some
form of MI or ischemia to explain the VT/VF. Proarrhyth-
Abbreviations and Acronyms
AVID  Antiarrhythmics Versus Implantable
Defibrillators trial
CAD  coronary artery disease
CHF  congestive heart failure
MI  myocardial infarction
NDIS  National Death Index Service
VF  ventricular fibrillation
VT  ventricular tachycardia
Table 1. Categories of Ventricular Tachyarrhythmias Compared
in This Study
Primary out-of-hospital cardiac arrest due to VF*† (n  992)
Documented out-of-hospital sustained VT with syncope*† (n  364)
Documented out-of-hospital sustained VT*† with left ventricular
ejection fraction 0.40 and:
Systolic blood pressure 80 mm Hg or
Near-syncope or
Chest pain or
Congestive heart failure
(n  512)
Documented out-of-hospital sustained VT* with left ventricular ejection
fraction 0.40 and:
Systolic blood pressure 80 mm Hg or
Near-syncope or
Chest pain or
Congestive heart failure
(n  145)
Out-of-hospital documented sustained VT or cardiac arrest due to VF
associated with an identified transient or correctable cause (n  278)
*No transient or correctable cause identified; †eligible for randomization in the main
AVID trial.
AVID  Antiarrhythmics Versus Implantable Defibrillators; VF  ventricular
fibrillation; VT  ventricular tachycardia.
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mic drug reaction and electrolyte imbalance was less com-
mon. The remainder of causes for VT/VF was variable.
Table 3 lists the baseline clinical characteristics of the
patients. The 278 patients with a presumed transient cause
for their arrhythmias are compared with the 2,013 patients
having out-of-hospital events deemed to be at high risk for
arrhythmia recurrence (primary VT/VF). Patients with
primary VT/VF were older, had a lower left ventricular
ejection fraction and were more likely to have had a prior
history of VT. They were also more likely to have had a
prior MI, CHF and revascularization procedures. Patients
whose VT/VF was deemed to have a reversible cause more
frequently had a history of coronary artery disease (CAD).
Figure 1 presents survival from the index event of patients
with primary VT/VF compared with patients who had a
transient or correctable cause identified. The upper panel
shows the unadjusted survivals. The lower panel shows
survivals after adjustment for five of the most important
covariables known to affect survival (age, ejection fraction,
CAD, coronary artery bypass grafting and use of aspirin).
No significant difference existed between the unadjusted
outcomes. However, outcome was actually worse (p 
0.008) in the group with VT/VF due to transient or
correctable causes after adjustment. A similar analysis using
22 covariables was nearly identical. Analysis of survival by
type of transient or correctable cause yielded no group that
had a significantly better survival (Fig. 2). However, the
number of subjects in each subgroup is small, and there are
multiple baseline and treatment differences between sub-
groups. Ventricular tachycardia or VF associated with non–
Q-wave MI or antiarrhythmia drug reaction seemed most
likely to presage better survival.
Table 4 lists the procedures and discharge therapies of
patients. Patients with primary VT/VF were less likely to
undergo revascularization surgery. They were more likely to
receive several drug therapies including digitalis, diuretics
and an angiotensin-converting enzyme inhibitor, and they
were less likely to receive a beta-blocker or aspirin. Patients
with VT/VF due to a transient or correctable cause were less
likely to receive specific antiarrhythmic therapy. Patients
with an ischemic transient or correctable cause for VT/VF
were more likely to be treated with revascularization, beta-
blockers and aspirin. They were less likely to receive a
specific antiarrhythmic therapy and therapy for heart failure.
DISCUSSION
VT/VF risk stratification. Central to the treatment of
patients who have life-threatening ventricular arrhythmias is
the concept of risk stratification (5,7). Patients at high risk
for recurrence need to be aggressively treated. Patients at
low risk do not need specific treatment for ventricular
arrhythmias. Usually included in assessment of the risk of
recurrence is an attempt to identify a transient or correctable
cause for the VT/VF. Until now, finding such a reversible
cause has been thought to suggest a low risk of recurrence
when the cause can be eliminated.
Ischemia and VT/VF reversibility. The most common
setting for life-threatening ventricular arrhythmias is myo-
cardial ischemia or scarring (4,5,8–12). The patient with
CAD without myocardial scarring who has a cardiac arrest
at the onset of ischemia (often induced by exercise) is
thought to be at low risk for recurrent arrhythmias when the
ischemia is successfully treated, commonly by some type of
revascularization procedure. This belief is based on a rather
small observational series (13). Many arrhythmia specialists
would assess such patients and direct the therapy with
programmed electrical stimulation studies after revascular-
ization (14).
MI and VT/VF reversibility. On the other hand, the
patient with a myocardial scar from a previous MI who has
sustained VT might be at higher risk for recurrent arrhyth-
mias because at least a part of the underlying cause (the
myocardial scar) cannot be completely eliminated (15). In
the context of this analysis, it should be acknowledged that
Table 2. Putative Transient or Correctable Causes of VT/VF
(n  278)
n %
Ischemic events 183 65.8%
New MI 161 57.9%
Non–Q-wave 83 29.9%
Q-wave 78 28.0%
Transient ischemia, no MI 22 7.9%
Other or unknown* 50 17.9%
Electrolyte imbalance 27 9.7%
Antiarrhythmic drug reaction 18 6.5%
*For example, cocaine or illicit drug use, sepsis, hypoxia, electrocution, drowning.
MI  myocardial infarction; VF  ventricular fibrillation; VT  ventricular
tachycardia.
Table 3. Comparison of Baseline Clinical Characteristics of
Patients With Primary VT/VF Versus VT/VF Due to Transient
or Correctable Causes
Primary
VT/VF
VT/VF Due to
Transient or
Correctable Cause p Value
n 2,013 278
Age (yrs) 63.4  12.3 61.0  12.7 0.004
LVEF 0.35  0.15 0.41  0.15  0.001
Men 76.6% 72.3% 0.132
CAD 74.9% 82.0% 0.004
Cardiomyopathy 3.1% 2.9% 0.851
Prior history
VF 4.3% 2.9% 0.206
VT 15.0% 9.7% 0.007
Atrial fibrillation 22.3% 18.7% 0.148
MI 57.5% 44.2%  0.001
CHF 38.4% 21.6%  0.001
Diabetes* 17.8% 15.8% 0.406
CABG/PTCA 26.2% 18.7% 0.003
AAD at index event 13.1% 13.7% 0.783
*Treated with insulin or oral hypoglycemics.
AAD  antiarrhythmic drug; CABG  coronary artery bypass graft surgery;
CAD  coronary artery disease; CHF  congestive heart failure; EF  left
ventricular ejection fraction; MI  myocardial infarction; PTCA  percutaneous
transluminal coronary angioplasty; VF  ventricular fibrillation; VT  ventricular
tachycardia.
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it is not always possible to know with certainty that a new
MI led to VT/VF or vice versa. For example, transthoracic
cardioversion in itself can result in transient ST-segment
elevation resembling that seen in acute MI (16).
Prognosis of VT/VF in the setting of MI. Previous
studies have suggested that the development of VF within
48 h of the onset of a new Q-wave MI (especially out-of-
hospital) is likely to identify a patient with a low risk of
recurrence after hospital discharge (4,5,8,10). Presumably,
the acute MI caused the VF cardiac arrest. If the region of
myocardium responsible for VF undergoes death and scar
formation, recurrence is unlikely. Ventricular tachycardia or
VF developing during the hospital admission, on the other
hand, is associated with increased mortality during the
initial hospitalization (17,18). This analysis does not distin-
guish between in-hospital and post-discharge mortality in
the patients with VT/VF thought to be due to a new MI.
Other causes and VT/VF reversibility. Other causes of
transient events are less common and highly variable. The
proarrhythmic effects of antiarrhythmic drugs are well
known (19,20). Occasionally patients being treated for
relatively minor arrhythmias can develop life-threatening
Figure 1. Survival curves comparing patients with high-risk ventricular tachycardia/ventricular fibrillation (Primary VT/VF) versus a transient/correctable
cause for the VT/VF (Transient VT/VF). Upper panel shows unadjusted data (p  NS), and the lower panel depicts results after adjustment for five
variables known to affect mortality (p  0.008, see text).
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arrhythmias because of the antiarrhythmic drug itself. Per-
haps these patients might already have underlying abnor-
malities of sodium or potassium conductance that is un-
masked or exacerbated by the antiarrhythmic drug. In these
patients, it has been thought that simple elimination of the
antiarrhythmic drug will remove the propensity to life-
threatening ventricular arrhythmias, though VT can usually
be induced at electrophysiologic study in most such patients
with structural heart disease (21), even after the drug is
stopped.
Patients with cardiac disease who are treated with diuret-
ics occasionally develop serious electrolyte abnormalities
that can precipitate ventricular arrhythmias (22,23). How-
ever, it is less well known whether correction of the
electrolyte abnormalities sufficiently removes the risk for
arrhythmia recurrence to forego other treatment. In this
study the patients with electrolyte abnormalities had the
worst prognosis, perhaps because many of them had severe
CHF requiring continued aggressive diuretic therapy, in
turn leading to more arrhythmias. Furthermore, it may be
difficult to determine whether hypokalemia is the cause or
result of VT/VF (24).
Uncertainty in determination of VT/VF reversibility.
Our study suggests that identification of low risk patients is
indeed difficult. In fact, many of the patients with a
transient or correctable cause were given long-term treat-
Figure 2. Survival curves for six subgroups of patients with a transient/correctable cause for their presenting ventricular tachycardia/fibrillation. The
subgroups are those listed in Table 2: non–Q-wave myocardial infarction (MI) (n  83), Q-wave MI (n  78) and ischemia-no MI (n  22) in the upper
panel. (Lower panel) Electrolyte imbalance (n  27), antiarrhythmic drug (AAD) reaction (n  18) and other or unknown (n  50). P  NS.
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ment, suggesting that the physician did not actually believe
that the patient was at low risk. Patients thought to be at
relatively low risk because their VT/VF was precipitated by
presumed transient or correctable causes experienced mor-
tality similar to, or worse than, that of patients with primary
VT/VF. Recurrent arrhythmias and subsequent arrhythmic
death in these patients are probably more common than
previously recognized. This paradox could be the result of
misclassification of a transient or correctable cause, failure to
fully correct the reversible cause or failure to identify other
underlying causes of arrhythmias that might not be reversed
by treating the obvious transient or correctable cause.
Furthermore, reversible causes may have been transiently
corrected but subsequently recurred. Such patients may have
severe structural heart disease that, in itself, accounts for the
bad prognosis. Thus, it is possible that there is indeed a high
intrinsic risk in these patients, even though the transient
cause is eliminated.
Clinical implications. These findings should cause the
physician to reassess their certainty that identification and
reversal of a transient or correctable cause in patients who
have an episode of life-threatening VT/VF precludes fur-
ther definitive treatment. Results from this study suggest
that greater diligence is required in treatment and follow-up
of these patients. Further evaluation of the relative contri-
bution of these transient or correctable causes, compared
with more permanent factors, is warranted. More research is
needed to identify truly reversible causes of VT/VF.
Study limitations. Identification of the presumed transient
or correctable cause of VT/VF could have been made in
error. Physicians attempted to identify all underlying struc-
tural heart disease, but the relative contribution between any
transient cause and the permanent factors may have been
incorrectly assessed. Nevertheless, the assignment to the
transient/correctable cause group was made on the best
judgment of experienced clinician-investigators and proba-
bly reflects actual clinical practice.
The AVID physician did not necessarily perform the
long-term follow-up. Transient or correctable factors may
have been incompletely treated or could have recurred.
Though therapy at discharge was recorded, it could have
been changed during long-term follow-up. Only data from
the index hospitalization associated with the episode of VT
or VF was recorded.
Nonfatal arrhythmia recurrence in patients with a tran-
sient or reversible cause for VT/VF was not followed. Only
death was identified. It is possible that causes of death other
than ventricular arrhythmias were responsible for our find-
ings. However, it is unlikely that nonarrhythmic causes of
death predominated in this population, which was younger
and generally healthier.
Conclusions. This study suggests that patients diagnosed
with “transient” or “correctable” causes for life-threatening
VT/VF have a high mortality risk. Such patients may have
a substrate for continued risk for serious arrhythmias. Ideal
therapy is unknown, but these patients probably require
more aggressive evaluation, treatment and follow-up than is
currently practiced. More research is needed to identify truly
reversible causes of VT/VF.
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Table 4. Comparison of Post-Event Procedures and Discharge Therapies
Primary
VT/VF
VT/VF Due to Transient or
Correctable Cause
Primary vs.
All p Value
Ischemic vs.
Other p Value
All
Patients
Ischemic
Patients
Other
Patients
CABG/PTCA 13.7% 42.8% 55.7% 13.7%  0.001  0.001
Beta-blocker 28.7% 45.1% 52.2% 28.7%  0.001  0.001
ACE inhibitor 58.8% 40.9% 42.5% 58.8%  0.001 0.460
ASA 56.7% 66.2% 72.1% 56.7%  0.001 0.005
Calcium channel blocker 14.3% 19.2% 18.8% 14.3% 0.049 0.810
Digitalis 38.8% 28.3% 29.3% 38.8%  0.001 0.610
Diuretics 44.3% 33.2% 33.0% 44.3%  0.001 0.910
Warfarin 23.1% 19.9% 21.4% 23.1% 0.212 0.350
AAD, no ICD 38.6% 26.0% 20.9% 38.6%  0.001 0.011
Amiodarone at discharge 38.4% 19.4% 15.3% 38.4%  0.001 0.025
ICD, no AAD 42.3% 16.9% 20.8% 42.3%  0.001 0.009
AAD and ICD 9.7% 3.6% 2.7% 9.7%  0.001 0.333
No AAD or ICD 9.5% 53.6% 55.7% 9.5%  0.001 0.320
AAD  antiarrhythmic drug; ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acid (aspirin); CABG  coronary artery bypass graft surgery; ICD  implantable
cardioverter defibrillator; PTCA  percutaneous transluminal coronary angiography; VF  ventricular fibrillation; VT  ventricular tachycardia.
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